Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01462357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
November 21, 2011
Completion date
October 27, 2015
Enrollment
1,079 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus